 Home > Biochemistry News > Biotechnology News > Johnson & Johnson's "Daratumumab" new indication for listing

Johnson & Johnson's "Daratumumab" new indication for listing

 Last Update: 2022-05-21
 Source: Internet
 Author: User

Tags

mm 5 8

antithrombin 3 high

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 15, the CDE official website showed that the new indication of Johnson & Johnson's daratumumab injection (subcutaneous injection) was applied for listing in China, and it is speculated that its indication may be multiple myeloma

From: CDE official website

Daratumumab is a humanized, anti-CD38 IgG1 monoclonal antibody developed by Johnson & Johnson

At present, daratumumab is a core product in Johnson & Johnson's oncology business.

Daratumumab sales over the years

From: Insight Database

The subcutaneous formulation developed by Johnson & Johnson for this blockbuster drug consists of a fixed-dose combination of daratumumab and recombinant human hyaluronidase PH20 (rHuPH20).

▼ Overview of the development of domestic and foreign indications for daratumumab

From: Insight Database

According to the Insight database, daratumumab subcutaneous injection submitted a marketing application to the NMPA in November 2020 and was prioritized as "clinically urgently needed drugs in short supply, innovative drugs and improved new drugs to prevent diseases such as major infectious diseases and rare diseases" review

Daratumumab intravenous injection has many indications under development, and these indications have the potential to become the potential development direction of subsequent subcutaneous injections (see the figure below for details)

Progress of daratumumab indications under development

From: Insight Database

Edit: plus one

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.